| Upregulated |
GO_BP |
GO:0006954∼inflammatory response |
30 |
1.30E−12 |
|
GO_BP |
GO:0007165∼signal transduction |
29 |
1.31E−02 |
|
GO_BP |
GO:0007155∼cell adhesion |
26 |
5.33E−08 |
|
GO_BP |
GO:0006955∼immune response |
24 |
1.76E−07 |
|
GO_BP |
GO:0042493∼response to drug |
21 |
5.92E−08 |
|
GO_BP |
GO:0045087∼innate immune response |
19 |
1.36E−04 |
|
GO_BP |
GO:0030198∼extracellular matrix organization |
18 |
1.08E−08 |
|
GO_BP |
GO:0050900∼leukocyte migration |
17 |
6.55E−11 |
|
GO_BP |
GO:0001525∼angiogenesis |
17 |
4.06E−07 |
|
GO_BP |
GO:0008284∼positive regulation of cell proliferation |
17 |
2.57E−03 |
|
GO_CC |
GO:0005886∼plasma membrane |
108 |
1.13E−09 |
|
GO_CC |
GO:0016021∼integral component of membrane |
107 |
2.03E−04 |
|
GO_CC |
GO:0070062∼extracellular exosome |
66 |
2.68E−04 |
|
GO_CC |
GO:0016020∼membrane |
64 |
4.11E−07 |
|
GO_CC |
GO:0005887∼integral component of plasma membrane |
62 |
6.07E−14 |
|
GO_CC |
GO:0005576∼extracellular region |
50 |
1.98E−06 |
|
GO_CC |
GO:0005615∼extracellular space |
49 |
2.48E−08 |
|
GO_CC |
GO:0009986∼cell surface |
31 |
1.08E−09 |
|
GO_CC |
GO:0005783∼endoplasmic reticulum |
20 |
4.86E−02 |
|
GO_CC |
GO:0000139∼Golgi membrane |
17 |
1.94E−02 |
|
GO_MF |
GO:0005515∼protein binding |
154 |
6.05E−03 |
|
GO_MF |
GO:0005524∼ATP binding |
36 |
6.15E−03 |
|
GO_MF |
GO:0042803∼protein homodimerization activity |
21 |
7.66E−03 |
|
GO_MF |
GO:0042802∼identical protein binding |
20 |
1.92E−02 |
|
GO_MF |
GO:0005102∼receptor binding |
19 |
7.41E−06 |
|
GO_MF |
GO:0004872∼receptor activity |
14 |
2.70E−05 |
|
GO_MF |
GO:0004672∼protein kinase activity |
12 |
2.09E−02 |
|
GO_MF |
GO:0005215∼transporter activity |
8 |
3.41E−02 |
|
GO_MF |
GO:0004888∼transmembrane signaling receptor activity |
8 |
4.43E−02 |
|
GO_MF |
GO:0005201∼extracellular matrix structural constituent |
7 |
5.17E−04 |
|
KEGG |
hsa04151: PI3K-Akt signaling pathway |
19 |
2.01E−04 |
|
KEGG |
hsa04510: Focal adhesion |
17 |
3.76E−06 |
|
KEGG |
hsa05200: Pathways in cancer |
17 |
5.96E−03 |
|
KEGG |
hsa04066: HIF-1 signaling pathway |
12 |
3.37E−06 |
|
KEGG |
hsa04015: Rap1 signaling pathway |
12 |
3.56E−03 |
|
KEGG |
hsa04145: Phagosome |
10 |
3.39E−03 |
|
KEGG |
hsa05205: Proteoglycans in cancer |
10 |
2.05E−02 |
|
KEGG |
hsa05150: Staphylococcus aureus infection |
9 |
1.14E−05 |
|
KEGG |
hsa04611: Platelet activation |
9 |
4.86E−03 |
|
KEGG |
hsa05133: Pertussis |
8 |
7.79E−04 |
| Downregulated |
GO_BP |
GO:0055114∼oxidation–reduction process |
33 |
3.33E−05 |
|
GO_BP |
GO:0034220∼ion transmembrane transport |
19 |
5.29E−06 |
|
GO_BP |
GO:0042493∼response to drug |
18 |
1.62E−03 |
|
GO_BP |
GO:0006811∼ion transport |
14 |
1.66E−05 |
|
GO_BP |
GO:0055085∼transmembrane transport |
14 |
8.16E−03 |
|
GO_BP |
GO:0007588∼excretion |
13 |
4.97E−11 |
|
GO_BP |
GO:0010628∼positive regulation of gene expression |
13 |
3.13E−02 |
|
GO_BP |
GO:0006814∼sodium ion transport |
12 |
4.94E−06 |
|
GO_BP |
GO:0001822∼kidney development |
12 |
8.92E−06 |
|
GO_BP |
GO:0008152∼metabolic process |
12 |
3.22E−03 |
|
GO_CC |
GO:0016021∼integral component of membrane |
171 |
4.63E−07 |
|
GO_CC |
GO:0070062∼extracellular exosome |
170 |
1.01E−33 |
|
GO_CC |
GO:0005886∼plasma membrane |
162 |
2.99E−12 |
|
GO_CC |
GO:0005887∼integral component of plasma membrane |
76 |
3.16E−11 |
|
GO_CC |
GO:0005615∼extracellular space |
50 |
1.87E−03 |
|
GO_CC |
GO:0016324∼apical plasma membrane |
44 |
4.39E−22 |
|
GO_CC |
GO:0016323∼basolateral plasma membrane |
28 |
2.05E−14 |
|
GO_CC |
GO:0009986∼cell surface |
24 |
5.53E−03 |
|
GO_CC |
GO:0005759∼mitochondrial matrix |
19 |
8.74E−04 |
|
GO_CC |
GO:0043025∼neuronal cell body |
15 |
1.88E−02 |
|
GO_MF |
GO:0042803∼protein homodimerization activity |
33 |
7.43E−04 |
|
GO_MF |
GO:0005509∼calcium ion binding |
29 |
7.77E−03 |
|
GO_MF |
GO:0043565∼sequence-specific DNA binding |
20 |
4.43E−02 |
|
GO_MF |
GO:0016491∼oxidoreductase activity |
13 |
3.24E−03 |
|
GO_MF |
GO:0046983∼protein dimerization activity |
11 |
3.31E−03 |
|
GO_MF |
GO:0008201∼heparin binding |
11 |
5.22E−03 |
|
GO_MF |
GO:0005088∼Ras guanyl-nucleotide exchange factor activity |
10 |
1.78E−03 |
|
GO_MF |
GO:0003824∼catalytic activity |
10 |
3.74E−02 |
|
GO_MF |
GO:0016787∼hydrolase activity |
10 |
4.07E−02 |
|
GO_MF |
GO:0046934∼phosphatidylinositol-4,5-bisphosphate 3-kinase activity |
9 |
1.10E−04 |
|
KEGG |
hsa01100: Metabolic pathways |
68 |
8.56E−08 |
|
KEGG |
hsa01130: Biosynthesis of antibiotics |
19 |
5.17E−05 |
|
KEGG |
hsa01200: Carbon metabolism |
11 |
1.83E−03 |
|
KEGG |
hsa04960: Aldosterone-regulated sodium reabsorption |
9 |
1.45E−05 |
|
KEGG |
hsa04978: Mineral absorption |
9 |
3.69E−05 |
|
KEGG |
hsa00010: Glycolysis / Gluconeogenesis |
9 |
7.57E−04 |
|
KEGG |
hsa04610: Complement and coagulation cascades |
8 |
4.14E−03 |
|
KEGG |
hsa04966: Collecting duct acid secretion |
7 |
1.11E−04 |
|
KEGG |
hsa00260: Glycine, serine and threonine metabolism |
7 |
9.10E−04 |
|
KEGG |
hsa00280: Valine, leucine and isoleucine degradation |
7 |
2.46E−03 |
